Browse the evidence

The symposium aimed to summarize key scientific evidence regarding dietary fats and CHD risk.

The symposium provided a platform for discussing scientific evidence on dietary fats.

Future clinical trials with other incretin mimetics may further emphasize the importance of an obesity phenotype-based approach in treating HFpEF.

Clinicians should stay informed about upcoming trials that may validate obesity phenotype-based treatments.

Final proof of efficacy for incretin therapies on primary clinical liver outcomes may come from large database analyses.

Future studies should focus on analyzing large datasets to confirm the efficacy of incretin therapies for NAFLD.

Cautious use of tirzepatide is vital due to potential adverse effects and contraindications.

Healthcare providers should monitor patients closely for adverse effects when prescribing tirzepatide.

Further interventional studies involving humans are needed to better understand the role of soy isoflavones in PCOS.

More research is necessary to fully understand how soy isoflavones can be effectively used in treating PCOS.

Strategies in supporting health and performance over a player's career are encouraged.

Organizations should hire qualified nutrition professionals to support players' long-term health.

Semaglutide's success in India will depend on affordability, rational prescribing, and integration into preventive care frameworks.

Efforts should focus on making semaglutide accessible and integrating it into broader health strategies.

Further investigations are warranted regarding the effects of GLP-1-based therapies on skeletal muscle.

Practitioners should advocate for more research to better understand the implications of GLP-1 therapies on muscle health.

It is important to avoid stigmatizing overweight and obesity in weight management.

Practitioners should be mindful of language and attitudes towards patients with overweight and obesity.

Physicians should persist in offering patients attention, support, and individualized treatment.

Practitioners should ensure they provide ongoing support and tailored treatment for patients.

This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) discusses 30 common obesity myths, misunderstandings, and/or oversimplifications.

Clinicians should be aware of these myths to improve patient care.

Knowledge of the underlying science may assist the obesity medicine clinician improve the care of patients with obesity.

Clinicians should leverage scientific knowledge to enhance patient outcomes.

The scientific support for this CPS is based upon published citations, clinical perspectives of OMA authors, and peer review.

The CPS is grounded in credible scientific and clinical perspectives.

Clinical inertia results in type 2 diabetes not being effectively managed.

Family physicians should be aware of the factors contributing to clinical inertia in T2D management.

Guidelines for antidiabetic drugs should provide case studies and clinical examples.

Improving guidelines with practical examples may enhance their application in clinical settings.

Clear recommendations for personalized T2D management may encourage drug prescription.

Family physicians should utilize clear recommendations to improve drug prescription practices.

Preoperative exercise training may improve walking test distance and body weight in adults undergoing bariatric surgery, but evidence is limited.

While evidence is limited, starting exercise before bariatric surgery may help improve walking test distance and body weight. Consult with your healthcare provider to determine if preoperative exercise training is appropriate for you.

Energy restriction is not supported by scientific evidence for improving glycemic control in Japanese patients with type 2 diabetes.

Current evidence does not support energy restriction as an effective standalone strategy for improving blood sugar in Japanese patients with type 2 diabetes, as studies show little to no benefit compared to other approaches.

Controlled metabolic accelerators (CMAs) like HU6 induce weight loss via increased mitochondrial energy expenditure (uncoupling) rather than caloric restriction, resulting in fat loss while sparing skeletal muscle mass in patients with obesity-related HFpEF.

This paper describes a new class of drugs (CMAs) that burn fat by speeding up metabolism rather than restricting food. In early studies, this approach reduced fat mass significantly while keeping muscle mass stable, unlike diet or surgery which often weaken patients. This trial tests if this works for heart failure patients with obesity. It is not a lifestyle intervention but a pharmaceutical one requiring medical supervision.

Modern obesogenic environments (sedentary lifestyle, high-calorie processed food) exploit evolutionary adaptations (brain expansion, efficient fat storage) leading to a 'normalization' of obesity phenotypes and genotypes.

Your environment is shaping your biology. To combat obesity, you must actively create a 'non-obesogenic' environment (healthy food access, physical activity) because your evolutionary biology is wired to store fat in such settings.

In the US, higher food insecurity is inversely associated with BMI.

If you are experiencing food insecurity, you may find your weight is lower than expected. This study suggests that in the US, food insecurity is linked to lower BMI, likely due to limited access to food. If you are struggling to afford food, prioritize nutrient-dense, affordable options and seek community resources. Your health is important, and help is available.

Ramadan Fasting (RF) protocols (28-30 days) have insufficient evidence to draw definitive conclusions regarding their effects on body weight, composition, or glycemic control compared to Time-Restricted Feeding.

Do not rely on Ramadan Fasting as a proven, standalone strategy for weight loss or metabolic health improvement based on current scientific evidence. The data is too sparse to recommend it over established methods like TRF.

There is no compelling evidence that non-sugar sweeteners provide important health benefits for weight loss in adults or children who are actively trying to lose weight, nor do they significantly improve glycaemic control or other major health outcomes compared to sugar.

If you are actively trying to lose weight, switching to non-sugar sweeteners is unlikely to provide a significant advantage over other methods. The evidence does not support using NSS as a primary tool for weight loss in this group. Focus on overall caloric deficit rather than just substituting sweeteners.

Dietary restriction of branched-chain amino acids can improve insulin sensitivity and increase energy expenditure in animal models, suggesting a potential therapeutic avenue for metabolic disease.

Animal studies suggest that reducing BCAA intake might help with insulin sensitivity. However, human data is mixed, with some studies showing higher dietary BCAA linked to lower T2D risk. Do not restrict protein without medical supervision.